Mizuho Securities analyst Difei Yang reiterated a Hold rating on Bluebird Bio (BLUE) today and set a price target of $34.00. The company’s shares closed last Tuesday at $25.62, close to its 52-week low of $24.24.
According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.8% and a 39.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $44.15, representing a 70.2% upside. In a report issued on February 16, William Blair also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
Bluebird Bio’s market cap is currently $1.7B and has a P/E ratio of -2.40. The company has a Price to Book ratio of 1.15.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
